C
CLEARMIND MEDICINE INC. COMMON SHARES
NASDAQ: CMND (Clearmind Medicine Inc.)
Last update: 14 hours ago6.22
0.37 (6.31%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Clearmind Medicine Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | -0.9 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.24 |
Select this tab to load the latest available analysis.
|
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.80% |
| % Held by Institutions | 10.91% |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |